4 results  1 of 1 

1 Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won
Diabetes Metab J.2023;47(1):82-91.   Published online 2022 June 20     DOI: http://dx.doi.org/10.4093/dmj.2021.0356
      
2 The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-World Data Study
Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek
Diabetes Metab J.2023;47(1):135-139.   Published online 2022 April 29     DOI: http://dx.doi.org/10.4093/dmj.2021.0373
      
3 Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors
Jun Hwa Hong
J Korean Diabetes.2019;20(2):87-91.   Published online 2019 June 30     DOI: http://dx.doi.org/10.4093/jkd.2019.20.2.87
      
4 The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication
Hyuk-Sang Kwon
J Korean Diabetes.2016;17(4):225-232.   Published online 2016 January 10     DOI: http://dx.doi.org/10.4093/jkd.2016.17.4.225
   

 1 of 1